



Express Mail Label No.: EV 312 158 636 US  
Docket No. JAB-1626

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicants : Lacrampe et al.

Serial No. : 09/891,888

Art Unit: 1624

Filed : June 26, 2001

Examiner: V. Balasubramanian

For : NOVEL IL-5 INHIBITING 6-AZAUACIL DERIVATIVES

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**RECEIVED**

**DEC 09 2003**

**TECH CENTER 1600/2900**

**INFORMATION DISCLOSURE STATEMENT**

Dear Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

☐ In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified national application (other than a continued prosecution application under

\$1.53(d)), within three months of the date of entry into the national stage of the above identified application as set forth in \$1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of a request for continued examination under \$1.114, no additional fee is required.

☐ In accordance with \$1.129(a), this Information Disclosure Statement is being filed in connection with ☐ the first or ☐ second After Final Submission, therefore:

- ☐ Statement in Accordance with \$1.97(e) (attached); or
- ☐ Please charge Deposit Account No. 10-0750/ / the fee of \$180.00 as set forth in \$1.17(p).

☒ In accordance with \$1.97(c), this Information Disclosure Statement is being filed after the period set forth in \$1.97(b) above but before the mailing date of either a Final Action under \$1.113 or a Notice of Allowance under \$1.311, or an action that otherwise closes prosecution and that it is accompanied by one of:

- ☐ Statement in Accordance with \$1.97(e) (attached); or
- ☒ Please charge Deposit Account No. 10-0750/JAB 1626/AGK the fee of \$180.00 as set forth in \$1.17(p).

☐ In accordance with \$1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under \$1.113 or a Notice of Allowance under \$1.311 but before the payment of the Issue Fee.

Applicant(s) hereby petition(s) for consideration of this Information Disclosure Statement. Included are: Statement in Accordance with §1.97(e) as set forth below and the fee of \$180.00 as set forth in §1.17(p).

☒ Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith.

☐ Copies of references listed on the attached Form PTO-1449 are enclosed herewith EXCEPT THAT:

☐ In view of the voluminous nature of references [list as appropriate], and the likelihood that these references are available to the Examiner, copies are not enclosed herewith.

☐ If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.

☐ There are no listed references which are not in the English language.

☐ The relevance of the listed reference which is not in the English language is as follows:

☒ Attached are the following non-published pending patent applications which may be deemed relevant, which are listed on the attached Submission Under MPEP 609 D:

(1) Amendment filed May 9, 2003 in U.S.S.N. 09/855,068, containing claims as currently pending in U.S.S.N. 09/855,068 (Attorney Ref. No. JAB 1609); (2) PCT International Search

Express Mail Label No.: EV 312 158 636 US  
Docket No. JAB-1626

Report for PCT Application No. PCT/EP 98/04191, mailed November 17, 1998, which relates to this corresponding U.S. Application, filed herewith.

Please charge any deficiency or credit any overpayment to Deposit Account No. 10-0750/JAB 1626/AGK. This form is submitted in triplicate.

Respectfully submitted,



Alana G. Kriegsman  
Reg. No. 41,747  
Attorney for Applicants

Johnson & Johnson  
One Johnson & Johnson Plaza  
New Brunswick, NJ 08933-7003  
(732) 524-1495  
DATED: December 1, 2003



Page 1 of 1

<b>Application Number</b>	09/891,888
<b>Filing Date</b>	Jun 26, 2001
<b>First Named Inventor</b>	Lacrampe et al.
<b>Group Art Unit</b>	1624
<b>Examiner Nam</b>	V. Balasubramanian
<b>Attorney Dock t Number</b>	JAB-1626

## U.S. PATENT DOCUMENTS

[illegible]

RECEIVED

DEC 09 2003

TECH CENTER 1600/2900

## FOREIGN PATENT DOCUMENTS

[illegible]

## OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

[illegible]

Examiner Signature	Date Considered
-----------------------	--------------------

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1

<b>Application Number</b>	Not yet Assigned
<b>Filing Date</b>	June 26, 2001
<b>First Named Inventor</b>	Lacrampe t al
<b>Group Art Unit</b>	1624
<b>Examiner Name</b>	V. Balasubramanian
<b>Attorney Docket Number</b>	JAB-1626

## U.S. PATENT DOCUMENTS

Examiner Initials	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear
		Number	Kind Code <sup>2</sup> (if known)			
		4,631,278		Boeckx et al	12/23/1986	
		4,767,760		Boeckx et al	08/30/1998	

## FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup>				
		EP	0831088	B1	Takeda Schering-Plough	03/25/1998		

## OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
		BAGGIOLINI, et al., "CC Chemokines in Allergic Inflammation." <u>Immunology Today</u> , 1994, pages 127-133, Vol. 15, No. 3	
		CARR et al., "Expression On Porcine $\gamma\delta$ lymphocytes Of A Phylogenetically Conserved Surface Antigen Previously Restricted In Expression $\gamma\delta$ T Lymphocytes." <u>Immunology</u> , 1994, pages 36-40, Vol. 81.	
		MINNICOZZI, M., "The inhibition of interleukin 5 in allergic diseases." <u>Expert Opinion on Therapeutic Patents</u> , 1999, pages 148-156, Vol. 9(2).	

Examiner Signature	Date Considered
-----------------------	--------------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450